$0.88
+0.08 (+10.27%)
Open$0.84
Previous Close$0.80
Day High$0.90
Day Low$0.82
52W High$4.47
52W Low$0.65
Volume—
Avg Volume155.4K
Market Cap8.31M
P/E Ratio—
EPS$-0.79
SectorBiotechnology
Analyst Ratings
Strong Buy
6 analysts
Price Target
+1,311.8% upside
Current
$0.88
$0.88
Target
$12.39
$12.39
$9.33
$12.39 avg
$15.15
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 3.16M | 3.05M | 3.43M |
| Net Income | -41,291 | -50,098 | -44,694 |
| Profit Margin | -1.3% | -1.6% | -1.3% |
| EBITDA | -71,807 | -61,818 | -76,890 |
| Free Cash Flow | -34,920 | -36,621 | -42,296 |
| Rev Growth | +21.0% | -5.0% | +24.8% |
| Debt/Equity | 0.35 | 0.39 | 0.35 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.87 | -1.20% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $354.05 | +0.63% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.73 | +0.98% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $449.71 | +0.71% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $776.21 | +0.46% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |